Alpha-synuclein Antibody (N-term) Blocking Peptide
€293.00
In stock
SKU
AC-BP6401a
Background:
Alpha Synuclein is implicated in the regulation of dopamine release and transport. It is a soluble protein, expressed principally in the brain but also expressed in low concentrations in all tissues examined (except liver). In the nervous system, alpha Synuclein is primarily located at presynaptic terminals and is found membrane bound in dopaminergic neurons. It can form filamentous aggregates that are the major non amyloid component of intracellular inclusions in several neurodegenerative diseases (synucleinopathies), including Parkinson's Disease. Alpha Synuclein induces fibrillization of microtubule associated protein tau and reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase 3 activation. Alpha synuclein is a protein phosphorylated predominantly on serine residues. Additional splicing may be present but the full-length nature of these variants has not been determined. This variant (NACP112) lacks an alternate in-frame segment, compared to variant NACP140, resulting in a shorter protein (isoform NACP112) that has a distinct C-terminus, compared to isoform NACP140. This antibody recognizes both NACP112 and NCAP140.
Other Names: Alpha-synuclein, Non-A beta component of AD amyloid, Non-A4 component of amyloid precursor, NACP, SNCA, NACP, PARK1
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP6401a was selected from the N-term region of human Alpha-synuclein. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Type: Synthetic peptide
Primary Accession: P37840
Other Accession: NP_009292
Gene ID: 6622
Gene Name: SNCA
Format: Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.
Bio References:
Kumru, H., et al., Ann. Neurol. 56(4):599-603 (2004).Pigullo, S., et al., Parkinsonism Relat. Disord. 10(6):357-362 (2004).Yao, D., et al., Proc. Natl. Acad. Sci. U.S.A. 101(29):10810-10814 (2004).West, A.B., et al., J. Biol. Chem. 279(28):28896-28902 (2004).Wang, F., et al., Genes Chromosomes Cancer 40(2):85-96 (2004).
Alpha Synuclein is implicated in the regulation of dopamine release and transport. It is a soluble protein, expressed principally in the brain but also expressed in low concentrations in all tissues examined (except liver). In the nervous system, alpha Synuclein is primarily located at presynaptic terminals and is found membrane bound in dopaminergic neurons. It can form filamentous aggregates that are the major non amyloid component of intracellular inclusions in several neurodegenerative diseases (synucleinopathies), including Parkinson's Disease. Alpha Synuclein induces fibrillization of microtubule associated protein tau and reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase 3 activation. Alpha synuclein is a protein phosphorylated predominantly on serine residues. Additional splicing may be present but the full-length nature of these variants has not been determined. This variant (NACP112) lacks an alternate in-frame segment, compared to variant NACP140, resulting in a shorter protein (isoform NACP112) that has a distinct C-terminus, compared to isoform NACP140. This antibody recognizes both NACP112 and NCAP140.
Other Names: Alpha-synuclein, Non-A beta component of AD amyloid, Non-A4 component of amyloid precursor, NACP, SNCA, NACP, PARK1
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP6401a was selected from the N-term region of human Alpha-synuclein. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Type: Synthetic peptide
Primary Accession: P37840
Other Accession: NP_009292
Gene ID: 6622
Gene Name: SNCA
Format: Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.
Bio References:
Kumru, H., et al., Ann. Neurol. 56(4):599-603 (2004).Pigullo, S., et al., Parkinsonism Relat. Disord. 10(6):357-362 (2004).Yao, D., et al., Proc. Natl. Acad. Sci. U.S.A. 101(29):10810-10814 (2004).West, A.B., et al., J. Biol. Chem. 279(28):28896-28902 (2004).Wang, F., et al., Genes Chromosomes Cancer 40(2):85-96 (2004).
| Is Featured? | No |
|---|
Write Your Own Review